Read the story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Last hour:
Last 24 hours:

MMJ Group invests A$1 million in unlisted Valo Therapeutics Oy

% of readers think this story is Fact. Add your two cents.

MMJ Group Holdings Ltd (ASX:MMJ, OTC:MMJJF) has completed an investment of A$1 million in the unlisted Valo Therapeutics Oy, as part of a total pre-initial public offering (IPO) equity financing of around US$13 million. 

The Finland-based immunotherapy company that is developing antigen-coated oncolytic viruses and vaccine vectors as therapeutic vaccines against cancer and infectious diseases, is preparing for an IPO in 2022. 

MMJ’s investment was made from the company existing cash reserves. 

Investment strategy

MMJ Group chair Peter Wall said: “The investment in Valo demonstrates MMJ’s expertise to secure a private negotiated investment in unlisted businesses, which are not generally available to Australian retail and institutional investors.

“Valo represents the continued deployment of funds in accordance with its investment strategy following the broadening of MMJ’s investment mandate in 2020.”

Validate PeptiCRADd platform

Valo Therapeutics CEO Paul Higham said: ”This successful financing is yet another significant milestone as we further validate our PeptiCRAd platform and now take the important step into the first clinical study.

“In addition, the financing will allow us to further validate our other oncology and infectious disease platforms and our pan Coronavirus T-cell vaccine.”

Valo Therapeutics successfully raised €11 million in an oversubscribed pre-IPO funding round, with participation coming from existing investors, Freeman Road, and new investors, MMJ.

The total raised to date is now over €22 million.

Valo Therapeutics

Valo Tx’s lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki.

It turns oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without the need to develop and manufacture multiple genetically modified viruses.

The company is seeking to fund the finalisation of preparations and initiation of a Phase 1 clinical study PeptiCRAd-1, in addition to the continued development of its anti-infectives platforms including PeptiBAC and PeptiVAX.

Story by ProactiveInvestors


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!

Order by Phone at 888-809-8385 or online at M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at M - F 9am to 5pm EST

Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Load more ...




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.